{"doi":"10.15326/jcopdf.2022.0332","title":"Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial","abstract":"Background: In the InforMing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler fluticasone furoate (FF) /umeclidinium (UMEC) /vilanterol (VI) significantly reduced severe exacerbation rates and all-cause mortality (ACM) risk versus UMEC/VI among patients with chronic obstructive pulmonary disease (COPD). This post hoc analysis aimed to define the risk of ACM during and following a moderate/severe exacerbation, and further determine the benefit-risk profile of FF/UMEC/VI versus FF/VI and UMEC/VI using a cardiopulmonary composite adverse event (AE) endpoint. Methods: The 52-week, double-blind IMPACT trial randomized patients with symptomatic COPD and ≥1 exacerbation in the prior year 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25mcg, FF/VI 100/25mcg, or UMEC/VI 62.5/25mcg. Post hoc endpoints included the risk of ACM during, 1-90 and 91-365 days post moderate or severe exacerbation and time-to-first cardiopulmonary composite event. Results: =0.006). Conclusion: Results confirm a substantial mortality risk during severe exacerbations, and an underlying CV risk. FF/UMEC/VI significantly reduced the risk of a composite cardiopulmonary AE versus UMEC/VI.","journal":"Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation","year":2022,"id":257057,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9653,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":250084,"name":"Gerard J. Criner","orcid":"0000-0003-1267-3483","position":1,"is_corresponding":false},{"id":491798,"name":"David Halpin","orcid":"0000-0003-2009-4406","position":2,"is_corresponding":false},{"id":250088,"name":"MeiLan K. Han","orcid":"0000-0002-9095-4419","position":3,"is_corresponding":false},{"id":906940,"name":"Renu Jain","orcid":"0000-0001-5400-2536","position":4,"is_corresponding":false},{"id":906941,"name":"Peter Lange","orcid":"0000-0003-0401-0081","position":5,"is_corresponding":false},{"id":464060,"name":"David A. Lipson","orcid":"0000-0001-6732-4593","position":6,"is_corresponding":false},{"id":33125,"name":"Fernando J. Martínez","orcid":"0000-0002-2412-3182","position":7,"is_corresponding":false},{"id":906942,"name":"Dawn Midwinter","orcid":"0000-0003-2434-1152","position":8,"is_corresponding":false},{"id":491800,"name":"Dave Singh","orcid":"0000-0001-8918-7075","position":9,"is_corresponding":false},{"id":350029,"name":"Robert A. Wise","orcid":"0000-0002-8353-2349","position":10,"is_corresponding":false},{"id":267138,"name":"J. Michael Wells","orcid":"0000-0001-9612-5454","position":0,"is_corresponding":true}],"reference_count":28,"raw_metadata":null,"created_at":"2026-07-19T00:25:30.183987Z","pmid":"36516330","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}